Nasal IL 1 Beta ,IL 3 Level and Their Effects in COPD Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

75 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-30

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic obstructive pulmonary disease is associated with systemic and local inflammation. exposure to harmful gases and particles play important role in initiating the inflammatory processes leading to the development of COPD. In high- and medium-income countries, tobacco smoking is considered the predominant source of these noxious elements.1 Asthma, COPD, rhinitis and rhinosinusitis (RS) are chronic diseases of the respiratory tract with an estimated global prevalence of about 12%.2The concept of united airways diseases (UAD) was formulated on the initial observation of the coexistence of allergic rhinitis and chronic rhinosinusitis with asthma.3

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Airway Inflammation, Symptoms and Lung Function in COPD

NCT01216592

Chronic Obstructive Pulmonary Disease

COMPLETED

Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00159341

Lung Diseases, Obstructive

COMPLETED PHASE1

Bronchial Infection in Patients With COPD and Frequent Exacerbations.

NCT03259022

Pulmonary Disease, Chronic Obstructive

UNKNOWN

The Mixed Phenotype of Asthma and COPD: the Overlap Syndrome

NCT03817333

Asthma COPD

COMPLETED

The Role of Congenital Mucosal Immune System in the Airways of Patients With Chronic Obstructive Pulmonary Disease

NCT04061122

COPD Exacerbation Smoking, Tobacco

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

. COPD patients asscioted with upper airway disease either high symptoms or low symptoms according to The 22-item Sino Nasal Outcome Test .Data will be collected through: History and examination of the upper airways and COPD symptomatology. History of smoking, medication, admission and acute exacerbation . Pulmonary function tests to confirm diagnosis and degree of obstruction. Diagnosis of COPD will be confirmed by the presence of irreversible airflow obstruction, post-bronchodilator FEV1/FVC ratio of less than 0.7. Severity of airflow obstruction will be graded according to the GOLD criteria \[9\] using CAT questionnaire to assess degree of COPD burden.\[10\] The 22-item Sino Nasal Outcome Test (SNOT22) will assess chronic rhinosinusitis symptoms and includes nasal and more general symptoms such as fatigue \[11\]. Each symptom is scored from 0 (no symptoms) to 5 (symptoms as bad as they can be"). The maximum score is 110, with an MCID of 9 points \[12\].

The SNOT22 nasal subdomain (SNOT22nasal) consists of seven questions (no. 1-5 + 7-8), which include: "need to blow nose", "sneezing", "runny nose", "nasal obstruction", "loss of smell or taste", "post-nasal discharge" and "thick nasal discharge". A cut-off for normality (or MCID) has been not validated, however the total SNOT22 has been found to have a median score of 7 points in healthy volunteers \[12\] Clinical markers in COPD symptom severity: Dyspnea will be graded using the mMRC 5-point scale.13 Physical Activity The 6MWD will be measured in accordance with the standard protocol with modifications.14 The latter were a shorter walking lap of 50 m instead of 60 m . Participants rested for 10 min before the test and then followed a straight corridor with a length of 25 m which was marked every 5 m. The turnaround points were set up with a red cone, and the distance walked in 6 minutes was recorded. Standardized phrases of encouragement were given during the test. Disease-specific HRQoL for COPD was measured by the CAT and the SGRQ questionnaires. The range of the total score is from 0 to 40 for the former and from 0 to 100 for the latter questionnaire, and high scores are indicative of poorer HRQoL

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Copd Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

copd patients with high upper airway symptoms

The SNOT22 nasal subdomain (SNOT22nasal) consists of seven questions (no. 1-5 + 7-8), which include: "need to blow nose", "sneezing", "runny nose", "nasal obstruction", "loss of smell or taste", "post-nasal discharge" and "thick nasal discharge". the total SNOT22 has been found to have a median score of 7 points in healthy volunteers

IL B,IL 3 in nasal swap and serum

Intervention Type DIAGNOSTIC_TEST

Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).

copd patients with low upper airway symptoms

The SNOT22 nasal subdomain (SNOT22nasal) consists of seven questions (no. 1-5 + 7-8), which include: "need to blow nose", "sneezing", "runny nose", "nasal obstruction", "loss of smell or taste", "post-nasal discharge" and "thick nasal discharge". the total SNOT22 has been found to have a median score of 7 points in healthy volunteers

IL B,IL 3 in nasal swap and serum

Intervention Type DIAGNOSTIC_TEST

Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IL B,IL 3 in nasal swap and serum

Interleukin (IL)-1-beta and IL-3 will be measured in patients' serum and supernatant from the nasal swap using enzyme linked immunosorbent assay (ELISA).

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ≥ 40 years
* History of smoking \> ten pack-years of tobacco
* Post- bronchodilator Forced Expiratory Volume 1 s (FEV1)/Forced Vital Capacity (FVC) index \<0.70.